Icotinib versus chemotherapy as adjuvant treatment for stage II–IIIA EGFR-mutant non-small-cell lung cancer (EVIDENCE): a randomised, open-label, phase 3 trial
Jianxing He(Southern Medical University), Caicun Zhou(Tongji University), Chunxia Su(Tongji University), Wenhua Liang(First Affiliated Hospital of Guangzhou Medical University), Taiqian Gong(Chinese PLA General Hospital), Wen Lin(Shantou University), Shidong Xu(Harbin Medical University), Jianying Zhou(Zhejiang University), Yunchao Huang(Kunming Medical University), Jian Zhao(ShanghaiTech University), Xiangning Fu(Tongji Hospital), Lin Wu(Materials Systems (United States)), Xiaoqing Liu(Jiangsu Province Hospital), Qun Chen(Virginia Commonwealth University), Yang Liu(Emory University), Chun Chen(Fujian Medical University), Zhong Lin Wang(Chongqing Medical University), Feng Ye(First Affiliated Hospital of Xiamen University), Zheng Wang(Shanghai Jiao Tong University), Haitao Ma(Soochow University), Lin Xu(First Affiliated Hospital Zhejiang University), Li Mao(Washington State University), Junke Fu(First Affiliated Hospital of Xi'an Jiaotong University), Zhidong Liu(Capital Medical University), Lieming Ding(Betta Pharmaceuticals (China)), Xingya Li(First Affiliated Hospital of Zhengzhou University), Guoguang Shao(Jilin University), Weimin Mao(Zhejiang Cancer Hospital), Di Ge(Fudan University), Jian Hu(First Affiliated Hospital Zhejiang University), Zemin Xiao(The First People's Hospital of Changde), Bing Hu(University of Science and Technology of China)
Cited by 183
Related Papers
Shape-Controlled Synthesis of Colloidal Platinum Nanoparticles
|Science|1996|2.4k
The 2020 report of The Lancet Countdown on health and climate change: responding to converging crises
|The Lancet|2020|1.9k
The 2022 report of the Lancet Countdown on health and climate change: health at the mercy of fossil fuels
|The Lancet|2022|1.6k